| Recruiting | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma NCT07081022 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Recruiting | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies NCT07239323 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies NCT06894693 | Guangdong Ruishun Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL NCT06314828 | Guangdong Ruishun Biotech Co., Ltd | Phase 1 |
| Recruiting | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma NCT06104553 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide NCT05771883 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 / Phase 2 |
| Unknown | Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL NCT05453669 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Suspended | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. NCT04697290 | Beijing Tsinghua Chang Gung Hospital | EARLY_Phase 1 |
| Completed | HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma NCT05190068 | Hutchmed | Phase 1 |
| Not Yet Recruiting | A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma NCT05091541 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lym NCT05436223 | Hrain Biotechnology Co., Ltd. | Phase 2 |
| Completed | A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma NCT05149391 | Peking University | Phase 1 |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT NCT04637763 | Caribou Biosciences, Inc. | Phase 1 |
| Suspended | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-H NCT04746131 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Completed | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma NCT04655677 | Peking Union Medical College Hospital | Phase 1 |
| Unknown | Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) NCT03639181 | Genor Biopharma Co., Ltd. | Phase 2 |
| Unknown | Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Trea NCT03417414 | Ottawa Hospital Research Institute | — |
| Unknown | Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) NCT03105596 | Peking University | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants Wi NCT02564744 | Debiopharm International SA | Phase 2 |
| Completed | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination W NCT02787239 | Shanghai Henlius Biotech | Phase 3 |
| Unknown | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma NCT02456207 | Sinocelltech Ltd. | Phase 2 |
| Completed | A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-ce NCT02584920 | Shanghai Henlius Biotech | Phase 1 / Phase 2 |
| Completed | Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patient NCT02206308 | Sinocelltech Ltd. | Phase 1 |
| Completed | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic NCT01351935 | Celgene | Phase 1 |
| Terminated | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymp NCT01352312 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia NCT00457782 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Unknown | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B NCT00927797 | Heidelberg University | Phase 2 |
| Completed | Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL NCT00588094 | Memorial Sloan Kettering Cancer Center | Phase 2 |